AD_____

AWARD NUMBER: W81XWH-08-1-0276

TITLE: Ovarian Carcinoma Stem Cells

PRINCIPAL INVESTIGATOR: Richard Jones, M.D.

CONTRACTING ORGANIZATION: Johns Hopkins University, School of Medicine
    Baltimore,   MD 21205

REPORT DATE: May 2009

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
                        Fort Detrick, Maryland 21702-5012

REPORT DOCUMENTATION PAGE

1. REPORT DATE	2. REPORT TYPE	3. DATES COVERED
1 May 2009	Final	15 Apr 2008 – 14 Apr 2009

4. TITLE AND SUBTITLE

Ovarian Carcinoma Stem Cells

5a. CONTRACT NUMBER

5b. GRANT NUMBER
W81XWH-08-1-0276

5c. PROGRAM ELEMENT NUMBER

6. AUTHOR(S)

Richard Jones, M.D.

E-Mail: rjjones@jhmi.edu

5d. PROJECT NUMBER

5e. TASK NUMBER

5f. WORK UNIT NUMBER

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)

Johns Hopkins University, School of Medicine
Baltimore, MD 21205

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

10. SPONSOR/MONITOR'S ACRONYM(S)

11. SPONSOR/MONITOR'S REPORT NUMBER(S)

12. DISTRIBUTION / AVAILABILITY STATEMENT
Approved for Public Release; Distribution Unlimited

13. SUPPLEMENTARY NOTES

14. ABSTRACT

Ovarian carcinoma is one of the most responsive solid tumors, with the majority of affected women now achieving complete remissions; unfortunately, most of these women eventually relapse and die from the disease. We hypothesized that the initial clinical responses represent therapeutic effectiveness against differentiated cancer cells making up the bulk of the tumor, while the high rate of relapses result from rare, biologically distinct resistant cancer stem cells (CSC). The limited understanding about the phenotype of normal ovarian epithelial stem cells is an obstacle to identifying ovarian CSC, if they exist. However, several characteristics that appear to be shared by normal stem cells from many tissues may serve as markers for CSC from many malignancies. We have developed one of the first true animal models of ovarian cancer, FNAR, a primary rat ovarian cancer that arose spontaneously (submitted for publication). FNAR parallels the human disease both biologically [expresses Her2/neu, estrogen receptors (ER) and androgen receptors (PR)] and clinically. The pan-stem cell marker ALDH expression appears to identify a CSC subpopulation from the FNAR cells, as the 2-4% of the cells expressing high levels of ALDH are enriched for both in vitro and in vivo clonogenic potential.

15. SUBJECT TERMS
No subject terms provided.

| 16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT	**b. ABSTRACT**	**c. THIS PAGE**	UU	28	**19b. TELEPHONE NUMBER** *(include area code)*
U	U	U			

Table of Contents

Introduction

Many cancers appear to arise from rare self-renewing cells that are biologically distinct from their more numerous differentiated progeny. Although the clinical significance of these so-called cancer stem cells (CSC) has been uncertain, recent data suggest that these cells are responsible for many of the relapses that follow anticancer therapy. Ovarian carcinoma is one of the most responsive solid tumors, with the majority of affected women now achieving complete remissions; unfortunately, most of these women eventually relapse and die from the disease. We hypothesized that the initial clinical responses in ovarian carcinoma represent therapeutic effectiveness against differentiated cancer cells making up the bulk of the tumor, while the high rate of relapses result from rare, biologically distinct CSC resistant to the therapies effective against the tumor bulk. The limited understanding about the phenotype of normal ovarian epithelial stem cells is an obstacle to identifying ovarian CSC, if they exist. However, several characteristics that appear to be shared by normal stem cells from many tissues, such as high expression of aldehyde dehydrogenase (ALDH) and the Hoechst side population (SP) phenotype, may serve as markers for CSC from many malignancies. The overall objective of this proposal is to further characterize and better understand the biology of CSC in ovarian carcinoma, with an eye toward improving therapeutic outcomes.

Body

Studies on the biology of ovarian cancer have been complicated by the absence of a good animal model for this disease. We have developed one of first true animal models of ovarian cancer, FNAR, that spontaneously arose in a Lewis rat (manuscript submitted, see Appendix). Upon intraperitoneal (IP) transplantation into rats, FNAR produces ascites and peritoneal implants; it can also be propagated *in vitro* as a cell line, that maintains the properties of the original tumor. The FNAR cells display striking similarities to human ovarian carcinoma biologically, as well as clinically. Histologically, the tumor is epithelial in origin, and expresses Her2/neu, estrogen receptors (ER), progesterone receptors (PR), and androgen receptors (AR). Gene expression profiling shows upregulation of a number of genes that are also upregulated in human ovarian carcinoma.

The development of this animal model has greatly facilitated our studies on ovarian CSC. Studies into identifying and characterizing CSC from hematologic malignancies have been possible because of a comprehensive understanding of cell surface antigen expression throughout lymphohematopoietic differentiation. In contrast, little is known about the cell surface phenotype associated with the growth and development of most non-lymphohematopoietic tissues. Thus, we have begun studying the ability of the pan-stem cell marker ALDH1 to identify ovarian CSC in the FNAR model. We found that 2-4% of the FNAR cells express high levels of ALDH. Moreover, the ALDH^{high} FNAR cells were significantly enriched for *in vitro* clonogenic potential (Fig 1A). IP injection of 50K FNAR cells leads to malignant ascites at 2-3 weeks, gross IP tumors between 6-8 weeks, and death of the rats between 12 -14 weeks. The cell populations (50K) separated by ALDH expression were injected IP into rats and preliminary results are available. The unfractionated cells generated malignant ascites at 2 weeks after IP transplantation with continued disease progression at 4 weeks (Fig 2B). The ALDH^{low} cells (>95% of the total cells) produced similar abdominal swelling and numbers of ascites tumor cells at 2 weeks, but the abdominal swelling and ascitic tumor cells disappeared. The ALDH^{high} cells produced no evidence of IP tumor growth at 2 weeks, but at 4 weeks produced more ascitic tumor cells than the ALDH^{low} cells. The ALDH^{high} cells produced large peritoneal tumors involving most of the peritoneal cavity by 2 months. The unfractionated cells produced

Fig 1A. Aldefluor enriches for clonogenic rat ovarian CA cells.

Fig 1B. ALDH expression distinguishes ovarian CA cells with short and long-term engraftment potential. Rat ovarian CA cells were separated by aldefluor and injected IP into rats.

only small peritoneal implants when the rats were sacrificed at 2 months, while rats receiving the ALDH^{low} cells showed no signs of ovarian cancer. Initial studies into characterizing the ALDH^{high} FNAR cells demonstrated that although ER, PR, and AR are expressed on the bulk FNAR cells, they are not expressed by the ALDH^{high} cells (Fig 2 a,b). Thus, ER, PR, and AR appear to be differentiation antigens for ovarian carcinoma. Conversely, Her2/neu is expressed equally on both populations (Fig 2c). Ovarian carcinoma cells from the malignant ascites of 2 patients


Fig 2A. Estrogen receptor expression in the FNAR rat ovarian carcinoma. The ALDH^{low} and unfractionated cells (not shown) express ER, while the ALDH^{high} cells do not.

Fig 2B. Androgen receptor expression in FNAR rat ovarian carcinoma. The ALDH^{low} and unfractionated cells (not shown) exhibit a clear AR population that represents about 30% of the total cells, while the ALDH^{high} express no AR.

Fig 2C. Both stem cell (ALDH^{high}) and differentiated cell (ALDH^{low}) subsets from the FNAR rat ovarian carcinoma express Her2/neu.

have also been studied for the presence of ovarian CSC. In both patients, the ALDH expression pattern paralleled that seen in FNAR cells, with about 1% of cells showing high ALDH expression (Fig 3). Full characterization of the ALDH^{high} expressing ovarian carcinoma cells from patients is underway.

Fig 3. ALDH expression of human ovarian carcinoma from malignant ascites. (A) About 1% of total cells are ALDH^{high} and (B) their Aldefluor fluorescence is eliminated by the ALDH inhibitor DEAB.

Key Research Accomplishments

- Development of one of the first spontaneously-occurring animal models for ovarian carcinoma
- Identification of a population of cells within the rat ovarian carcinoma that has phenotypic and functional characteristics consistent with their being the CSC (i.e., cancer-initiating cells).

Reportable Outcomes

Manuscript: Sharrow AC, Ronnett BM, Thoburn CJ, Barber JP, Giuntoli RJ, Armstrong DK1, Jones RJ, Hess AD. Identification and characterization of a spontaneous ovarian carcinoma in Lewis rats. Submitted 2009.

Grant submitted and funded: DOD grant OC080269 - "Targeting Cancer Stem Cells" (W81XWH-09-1-0129; PERIOD OF PERFORMANCE: 1 May 2009 - 31May 2012 (Research Ends 30 April 2012)

Conclusion

Using a newly spontaneously-developing rat model of ovarian carcinoma, a small population of ALDH^{high} cells appear to be the cells responsible to the growth and development of the tumor both *in vitro* and *in vivo*. Like breast cancer stem cells, this cell population does not apppear to express sex hormone receptors. However, unlike breast cancer stem cells, the ovarian carcinoma CSC do appear to express Her2/neu. Preliminary data suggest that a similar subpopulation is present in primary explanted patient samples. Principles developed in this animal model will be used to perform similar studies in human ovarian carcinoma cell lines and then clinical ovarian carcinoma specimens.

Appendix

1

Identification and characterization of a spontaneous ovarian carcinoma in Lewis rats.

Allison C. Sharrow[1], Brigitte M. Ronnett[2,3], Christopher J. Thoburn[1], James P. Barber[1], Robert L. Giuntoli II[1,3], Deborah K. Armstrong[1], Richard J. Jones[1] and Allan D. Hess[1]

The Sidney Kimmel Comprehensive Cancer Center[1], Department of Pathology[2] and Department of Gynecology and Obstetrics[3], Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA

Running Title: Rat Model of Ovarian Carcinoma

Keywords: rat, model, ovarian carcinoma, estrogen receptor α, progesterone receptor, androgen receptor, and her-2/neu

Address correspondence to: Richard J. Jones, Room 244, Bunting-Blaustein Cancer Research Building, 1650 Orleans St., Baltimore, MD 21231, Phone: 410-955-2006 FAX: 410-614-7279, email: rjjones@jhmi.edu

1   **ABSTRACT**

2   **Objective**

3   Ovarian carcinoma is the fourth most common cause of death from cancer in

4   women. Unfortunately, limited progress has been made toward improving the survival

5   rate of patients with this disease. One obstacle to the development of new therapies for

6   ovarian cancer has been the lack of a good animal model. We present here a model of

7   spontaneous ovarian carcinoma arising in a normal Lewis rat.

8   **Methods**

9   The tumor was passages *in vivo* by intraperitoneal injection into

10   immunocompetent Lewis rats. Tumors were sectioned for histological examination. A

11   resulting cell line can be cultured *in vitro*. Cells were examined by flow cytometry for

12   expression of estrogen receptor α, progesterone receptor, androgen receptor, her-

13   2/neu, and Ep-CAM. RNA was harvested from cells for gene expression profiling and

14   for studying the expression of cytokines.

15   **Results**

16   The tumor, designated FNAR, can be transplanted into Lewis rats and

17   propagated as a cell line *in vitro*, maintaining the properties of the original tumor. The

18   FNAR cells display striking similarities to human ovarian carcinoma, resembling the

19   endometrioid carcinoma subtype of surface epithelial neoplasms. The cells express

20   estrogen receptor α, progesterone receptor, androgen receptor, her-2/neu, and Ep-

21   CAM. A gene expression profile shows upregulation of a number of genes that are also

22   upregulated in human ovarian carcinoma.

23   **Conclusion**

1   This reliable model of ovarian carcinoma should be helpful in better

2   understanding the biology of the disease as well as the development of novel treatment

3   strategies.

4

INTRODUCTION

1

2 Ovarian cancer is the fifth most commonly diagnosed cancer in women and the

3 fourth most common cause of death from cancer [1]. The high mortality can be

4 attributed to the high percentage of affected women presenting at an advanced stage,

5 with spread within the peritoneal cavity [2, 3]. With current therapies, including surgical

6 debulking and platinum-based chemotherapy, patients in stage III or stage IV only have

7 a 20% chance of long-term survival [2, 3]. Better understanding ovarian carcinoma

8 biology, as well as the development of new therapies for the disease, has been

9 hampered by the lack of suitable animal models.

10 Current ovarian cancer models fall into three broad categories: rare spontaneous

11 carcinomas, induced tumors, and human xenografts [4]. These models have allowed

12 researchers to gain valuable insight. However, as described in detail by Garson et. al.

13 and Vanderhyden et. al., these models have deficiencies [4, 5]. Spontaneous ovarian

14 cancer has been observed in mice, rats, and hens [6-8]. The drawback to these models

15 is that the cancers tend to occur at an advanced age and at similar low frequencies as

16 in humans. The low incidence and the length of time required for the development of

17 these tumors render them of limited use for studying the biology and treatment of

18 ovarian carcinoma. Induced tumor models circumvent these problems but create their

19 own artificial systems, which may not accurately reflect the human disease. In one

20 model of *in vitro* transformation, ovarian surface epithelium cells are subcloned until

21 they exhibit the loss of contact inhibition, the capacity for substrate-independent growth,

22 cytogenetic abnormalities, and the ability to form tumors when injected subcutaneously

23 and/or intraperitoneally into athymic mice [9]. This model, though, fails to account for

1 critical interactions between the cancer cells and the host. Also, it is uncertain if these

2 cells or their malignant transformation are representative of normal human cells or

3 clinical disease. Animal models have been generated by expressing simian virus 40

4 large T antigen [10], by inactivating p53 and Rb1 [11], by inactivating p53 and activating

5 an oncogene [12], and through hormone treatment [13-15]. The high rate of cancer

6 development in these animals makes these models attractive, but they may not reliably

7 represent human cancer because these genetic changes usually do not occur in

8 patients. Xenografts of human cancers have undergone continuous improvement over

9 the past twenty years [16-19]. These models allow for direct examination of the human

10 cancer but do not allow the study of the early stages of the cancer. These models also

11 rely on an immune-deficient host, which eliminates the interaction between the cancer

12 and the immune system.

13 We present a new model of ovarian carcinoma, designated FNAR, that

14 spontaneously developed in an untreated, previously normal Lewis rat. The ovarian

15 tumor was harvested and transplanted into normal Lewis rats. In addition, an *in vitro*

16 cell line and clones were generated from the tumor. Importantly, this model fully

17 simulates human ovarian carcinoma by cell biology and growth characteristics.

18

19 **MATERIALS AND METHODS**

20 **Animals.** Female Lewis strain rats aged 4-6 weeks (purchased from Charles

21 River Breeding Laboratories, Inc., Wilmington, MA) were kept in sterile micro-isolator

22 cages and fed food and water *ad libitum*. Institutional guidelines concerning the care

23 and use of research animals were followed. The animals were challenged

1   intraperitoneally with graded numbers of FNAR cells and monitored daily for abdominal

2   swelling. At various intervals after tumor challenge or when animals appeared

3   moribund (pallor, lethargy, and marked abdominal distension) the animals were

4   sacrificed by CO_2 asphyxiation and the cells within the peritoneal cavity harvested by

5   flushing the abdomen with 35 milliliters of sterile phosphate buffered saline (PBS, Grand

6   Island Biological Co., Gibco BRL, Grand Island, NY). At sacrifice, the animals were

7   examined for tumor growth and tissues taken for histological examination. Slides were

8   photographed at 200x with an Olympus DP70 digital camera.

9

10   *In vitro* **propagation and growth curve.** A cell line (FNAR) that grows *in vitro*

11   as an adherent monolayer was established by culture in RPMI 1640 (Gibco)

12   supplemented with 10% fetal calf serum in 30 ml tissue culture flasks (Corning Flask

13   3056, Corning Inc., Corning NY). Cells used for experiments were low passage and

14   maintained in culture for one to three months. The doubling time of the cell line was

15   measured by plating 10^4 cells into macrotiter wells then harvesting and counting at 19.5,

16   43.5, and 115.5 hours.

17

18   **Flow Cytometric Analysis.** Flow cytometry was utilized to assess *in vitro* FNAR

19   cells for expression of known phenotypic markers. Briefly, 5 x 10^5 tumor cells were

20   incubated in polystyrene tubes. Analysis of the intracellular antigens estrogen receptor

21   α, progesterone receptor, and androgen receptor first required fixation in 2%

22   formaldehyde (Polysciences, Warrington, PA) in phosphate buffered saline (PBS, Gibco

23   Invitrogen, Carlsbad, CA) for 15 minutes at 4°C followed by permeabilization with 0.1%

Triton-X-100 (Sigma-Aldrich, St. Louis, MO) in PBS for 15 minutes at 4°C. The cells

were then incubated for 30 minutes at 4°C with commercially purchased murine

monoclonal antibodies. The concentrations of antibodies used are as follows: estrogen

receptor (ER) α at 8 μg/10^6 cells (Abcam, Cambridge, MA), progesterone receptor (PR)

at 16 μg/10^6 cells (Affinity Bioreagents, Golden, CO), or androgen receptor (AR) at 2

μg/10^6 cells (Pharmingen, San Diego, CA). The cells were washed and counterstained

with phycoerythrin (PE) rat anti-mouse IgG$_1$ (Becton Dickinson, San Jose, CA) at 125

ng/10^6 cells for 30 minutes at 4°C. Commercially purchased murine monoclonal

antibody to the rat c-neu oncogene product (Calbiochem, San Diego, CA) was used at 1

μg/10^6 cells and was counterstained with PE rat anti-mouse IgG$_{2a+b}$ (Becton Dickinson,

San Jose, CA) at 30 ng/10^6 cells for 30 minutes at 4°C. Tumor cells incubated with

secondary antibody alone served as a negative control. Ep-CAM expression was

analyzed using a PE-conjugated antibody (Santa Cruz, Santa Cruz, CA) at 1 μg/10^6

cells with mouse IgG$_1$-PE as a negative control (Becton Dickinson, San Jose, CA). The

cells were analyzed on a Becton-Dickinson FACSCalibur flow cytometer and data was

analyzed using FlowJo (Tree Star, Inc, Ashland, OR).

Gene Expression Analysis by cDNA Microarrays. RNA was extracted and

purified from cell lysates of 1-5 x 10^5 *in vitro* FNAR tumor cells and the REH cell line of

normal rat endothelial cells with 500 µl Trizol reagent (Invitrogen, Carlsbad, CA). Tissue

samples were frozen in liquid nitrogen and pulverized with a mortar and pestle. The

powder was dissolved in Trizol and centrifuged. Purified RNA was dissolved in 20µl

diethyl-pyrocarbonate-treated distilled water. The resulting RNA was analyzed at the

1   Johns Hopkins microarray core. RNA from control and experimental samples was

2   processed using the RNA amplification protocol described by Affymetrix (Affymetrix

3   Expression Manual). Briefly, 5 µg of total RNA was used to synthesize first strand

4   cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, California) and

5   oligonucleotide primers with 24 oligo-dT plus the T7 promoter (Proligo LLC, Boulder,

6   Colorado). Following the double stranded cDNA synthesis, the product was purified by

7   phenol-chloroform extraction and biotinilated anti-sense cRNA was generated through

8   *in vitro* transcription using the BioArray RNA High Yield Transcript Labeling kit (ENZO

9   Life Sciences Inc., Farmingdale, New York). Fifteen μg of the biotinilated cRNA was

10   fragmented at 94°C for 35 minutes in buffer (100mM Tris-acetate, pH 8.2, 500mM

11   potassium acetate, and 150mM magnesium acetate), and 10μg of total fragmented

12   cRNA was hybridized to the Affymetrix GeneChip rat 230 2.0 array (Santa Clara, CA)

13   for 16 hours at 45ºC with constant rotation (60 rpm). Affymetrix Fluidics Station 450

14   was then used to wash and stain the chips with a streptavidin-phycoerythrin conjugate.

15   The staining was then amplified as follows: blocking was performed using goat IgG,

16   then a biotinilated anti-streptavidin antibody (goat) was bound to the initial staining, and

17   amplification was completed by the addition of a streptavidin-phycoerythrin conjugate.

18   Fluorescence was detected using the Affymetrix 3000 7G GeneArray Scanner and

19   image analysis of each GeneChip was done through the GeneChip Operating System

20   1.4.0 (GCOS) software from Affymetrix using the standard default settings. For

21   comparison between different chips, global scaling was used to scale all probesets to a

22   user defined target intensity (TGT) of 150.

23

1   **Quantitative RT-PCR for Cytokine Expression.** Quantitative RT-PCR

2 (Taqman, Applied Biosystems, ABI, Foster City, CA) was utilized to assess levels of

3 cytokine mRNA transcripts of *in vitro* FNAR cells as previously described [20]. The

4 oligonucleotide primers and fluoresceinated probes for the cytokine genes (IL-6, IL-12,

5 and IL-18) were purchased from ABI. Data were analyzed in real-time with Sequencer

6 Detection version 1.6 software, with the results normalized against mRNA transcripts for

7 the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GADPH).

8

9 **RESULTS**

10   **Description of proband**. Examination of a normal female Lewis rat sacrificed

11 for harvesting normal splenic T cells showed a spontaneously occurring tumor

12 (approximately 0.5 cm^3) derived from the left ovary and attached to and invading the

13 abdominal wall (Figure 1A). In addition, tumor studding was observed at several sites

14 on the wall of the peritoneum, and ascites was present. Histologically, the tumor is an

15 epithelial neoplasm with features most consistent with an adenocarcinoma (Figure 1B).

16 It is composed of nests displaying admixed cribriform and solid architecture. The tumor

17 cells have modest amounts of amphophilic / eosinophilic cytoplasm and relatively

18 uniform oval nuclei that are predominantly vesicular to modestly hyperchromatic and

19 have small nucleoli. Occasional mitotic figures and apoptotic bodies are noted, as is

20 focal necrosis. Based on analogy to human ovarian epithelial tumors, this most closely

21 resembles an endometrioid carcinoma (a cribriform variant of that subtype, with cells

22 being less columnar than the classical human endometrioid carcinoma). Lymphocyte

23 infiltration into the tumor mass was minimal at best, although numerous lymphocytes

1 were present in the peritoneal fluid. The tumor was excised and pushed through a 100

2 micron wire mesh screen to obtain a single cell suspension.

3

4 ***In vivo* and *in vitro* growth characteristics.** Normal Lewis rats were given

5 either intraperitoneal (IP) or subcutaneous injection of graded numbers (5 x 10^4, 1 x 10^5,

6 5 x 10^5, or 1 x 10^6) of tumor cells. The animals were monitored daily for overall general

7 health as well as degree of abdominal extension. The tumor repeatedly failed to grow

8 subcutaneously, even with the administration of systemic immunosuppression

9 (Cyclosporine, 10 mg/kg/d) or passage into thymectomized animals. However, all rats

10 became moribund at 150-160 days after IP injection with 5 x 10^5 or 1 x 10^6 cells (Table

11 1). Rats injected with 1 x 10^5 cells became moribund around 175 days. Rats receiving

12 IP injections of 5 x 10^4 cells generally did not appear ill by 6 months, but tumor cells

13 were detected in the peritoneal cavity when sacrificed on day 175. Tumor growth

14 recapitulated that seen in the initial rat with IP tumoral masses adhering to all of the

15 visceral organs and the abdominal wall. Histologically, the tumors appeared to be of

16 epithelial origin. This was confirmed by expression of Ep-CAM using flow cytometry

17 (Figure 3E). Affected rats also showed enlargement of the ovaries and fallopian tubes,

18 with a marked increase in vascularization. Successful serial passage was conducted by

19 IP challenge with 1 X 10^5 tumor cells harvested by flushing of the peritoneal cavity.

20 The doubling time of the FNAR cell line was measured by plating 10^4 cells into

21 macrotiter wells then harvesting and counting at 19.5, 43.5, and 115.5 hours (Figure 2).

22 The slope of the line of log number of tumor cells versus hours estimates a doubling

23 time of 22.9 hours.

1

Biological characterization of FNAR. Like the clinical presentation, the

phenotype of this tumor most resembled epithelial ovarian carcinoma. ER is detected in

60-90% of ovarian carcinomas [21-25], 25-50% express PR [21, 23-26], and 45%

expressed both [23, 25]. AR is expressed in 50-70% of ovarian carcinomas [24, 26].

Accordingly, in the appropriate clinical setting, sex hormone receptor expression is

diagnostic of ovarian carcinoma [25, 27]. The tumor expressed ER, PR, and AR by flow

cytometry (Figure 3A-C), with ER and PR confirmed by PCR (data not shown). The

tumor also expressed her-2/neu (Figure 3D), which is expressed in 25-35% of ovarian

carcinomas [28, 29]

Gene expression profiling demonstrated that FNAR gene expression was similar

to that reported for human ovarian carcinoma (Table 2). Metallothioneins are generally

not found at immunohistochemically detectable levels in normal cells, but their

expression increases in ovarian carcinoma with increasing grade [30-32].

Metallothionein I was overexpressed 11.38-fold in FNAR cells when compared to

endothelial cells, and metallothionein II showed 3.56-fold increased expression.

Thioredoxin expression correlates with cis-diaminedichloroplatinum resistance [33] and

is expressed in FNAR cells 3.07-fold higher than in endothelial cells. Stathmin

regulates microtubules during the formation of the mitotic spindle and is not expressed

at detectable levels in normal cells; however, high-level expression is generally seen in

ovarian carcinoma [34-36]. Accordingly, stathmin expression was 3.23-fold higher in

FNAR cells than in endothelial cells. A nuclear factor that it is involved in cell cycle

1 progression, b-myb, is also highly expressed in both FNAR cells (3.33-fold) and human

2 ovarian carcinoma [37].

3 High levels of interleukin-6 (IL-6), a proinflammatory cytokine and hematopoietic

4 growth factor, are found in both normal ovarian epithelium and human ovarian

5 carcinoma [38, 39]. Interleukin-18 (IL-18) is a proinflammatory cytokine that stimulates

6 interferon-γ production. Ovarian carcinoma expresses IL-18, but it is predominantly the

7 pro-IL-18 form [40]. Interleukin-12 (IL-12) is a cytokine that encourages a T_h1 immune

8 response. IL-12 has been detected in ascites fluid and serum of ovarian cancer

9 patients [41], although no reports have examined the expression of IL-12 by the ovarian

10 carcinoma cells themselves. Expression of all three cytokines by FNAR cells was

11 detected by real time RT-PCR (Figure 4).

12

13 **DISCUSSION**

14 We present here a model of ovarian carcinoma, designated FNAR, that arose

15 spontaneously in a normal Lewis rat. IP transplantation into rats produces malignant

16 ascites and peritoneal carcinomatosis, leading to death at 5-6 months. Cells from the

17 tumor can be easily passaged *in vitro,* and the cell line shows similar growth

18 characteristics when returned to rats. FNAR's biology closely parallels the human

19 disease. It appears to be epithelial in origin by histology and expression of Ep-CAM.

20 Like human ovarian carcinoma, it expresses her-2/neu, sex hormone receptors, and

21 characteristic cytokines. It displays a similar gene expression pattern to the human

22 disease. The tumor only develops in the peritoneal cavity, suggesting the tumor

23 microenvironment is intact during formation.

1   The FNAR model overcomes many of the limitation of current model systems for

2   ovarian carcinoma. Rats transplanted with FNAR consistently become moribund by 5-6

3   months, overcoming the low frequency and long latency of spontaneous animal models.

4   Xenografts of primary human tumors in immunodeficient mice are perhaps the most

5   attractive current model [16-19]. Although spontaneous human cancers can be studied

6   and used to test treatments in these mice, the study of immunotherapeutic approaches

7   is problematic. Conversely, FNAR develops in immunocompetent rats, allowing the

8   study of immunotherapeutic approaches. The expression of all three sex hormone

9   receptors and her-2/neu also allows for manipulations of these pathways using this

10   model. However, the relevance of this model to the treatment of human disease still

11   remains to be established.

12

13   **CONFLICT OF INTEREST STATEMENT**

14   The authors declare that there are no conflicts of interest.

Reference List

[1]   Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer Statistics, 2004. CA Cancer J Clin. 2004 January 1, 2004;54(1):8-29.

[2]   Cannistra SA. Cancer of the ovary. The New England Journal of Medicine. 1993;329:1550-9.

[3]   Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer. N Engl J Med. 2006 January 5, 2006;354(1):34-43.

[4]   Garson K, Shaw TJ, Clark KV, Yao D-S, Vanderhyden BC. Models of ovarian cancer--Are we there yet? Molecular and Cellular Endocrinology. 2005;239(1-2):15-26.

[5]   Vanderhyden B, Shaw T, Ethier J-F. Animal models of ovarian cancer. Reproductive Biology and Endocrinology. 2003;1(1):67.

[6]   Beamer WG, Hoppe PC, Whitten WK. Spontaneous Malignant Granulosa Cell Tumors in Ovaries of Young SWR Mice. Cancer Res. 1985 November 1, 1985;45(11 Part 2):5575-81.

[7]   Walsh KM, Poteracki J. Spontaneous Neoplasms in Control Wistar Rats. Fundamental and Applied Toxicology. 1994;22(1):65-72.

[8]   Fredrickson TN. Ovarian Tumors of the Hen. Environmental Health Perspectives. 1987 1987;73:35-51.

[9]   Godwin AK, Testa JR, Handel LM, Liu Z, Vanderveer LA, Tracey PA, et al. Spontaneous Transformation of Rat Ovarian Surface Epithelial Cells: Association With Cytogenetic Changes and Implications of Repeated Ovulation in the Etiology of Ovarian Cancer. J Natl Cancer Inst. 1992 April 15, 1992;84(8):592-601.

[10]   Connolly DC, Bao R, Nikitin AY, Stephens KC, Poole TW, Hua X, et al. Female Mice Chimeric for Expression of the Simian Virus 40 TAg under Control of the MISIIR Promoter Develop Epithelial Ovarian Cancer. Cancer Res. 2003 March 15, 2003;63(6):1389-97.

[11]   Flesken-Nikitin A, Choi K-C, Eng JP, Shmidt EN, Nikitin AY. Induction of Carcinogenesis by Concurrent Inactivation of p53 and Rb1 in the Mouse Ovarian Surface Epithelium. Cancer Res. 2003 July 1, 2003;63(13):3459-63.

[12]   Orsulic S, Li Y, Soslow RA, Vitale-Cross LA, Gutkind JS, Varmus HE. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell. 2002;1(1):53-62.

[13]   Keri RA, Lozada KL, Abdul-Karim FW, Nadeau JH, Nilson JH. Luteinizing hormone induction of ovarian tumors: Oligogenic differences between mouse strains

dictates tumor disposition. Proceedings of the National Academy of Sciences. 2000 January 4, 2000;97(1):383-7.

[14]   Bai W, Oliveros-Saunders B, Wang Q, Acevedo-Duncan ME, Nicosia SV. Estrogen stimulation of ovarian surface epithelial cell proliferation. In Vitro Cellular& Developmental Biology - Animal. 2000 November 01, 2000;36(10):657-66.

[15]   Silva EG, Tornos C, Deavers M, Kaisman K, Gray K, Gershenson D. Induction of Epithelial Neoplasms in the Ovaries of Guinea Pigs by Estrogenic Stimulation. Gynecologic Oncology. 1998;71(2):240-6.

[16]   Hamilton TC, Young RC, Louie KG, Behrens BC, McKoy WM, Grotzinger KR, et al. Characterization of a Xenograft Model of Human Ovarian Carcinoma Which Produces Ascites and Intraabdominal Carcinomatosis in Mice. Cancer Res. 1984 November 1, 1984;44(11):5286-90.

[17]   Molpus KL, Koelliker D, Atkins L, Kato DT, Buczek-Thomas J, Fuller Jr AF, et al. Characterization of a xenograft model of human ovarian carcinoma which produces intraperitoneal carcinomatosis and metastases in mice. International Journal of Cancer. 1996;68(5):588-95.

[18]   Rose GS, Tocco LM, Granger GA, DiSaia PJ, Hamilton TC, Santin AD, et al. Development and characterization of a clinically useful animal model of epithelial ovarian cancer in the Fischer 344 rat. American Journal of Obstetrics and Gynecology. 1996;175(3):593-9.

[19]   Sallinen H, Anttila M, Narvainen J, Orden M-R, Ropponen K, Kosma V-M, et al. A highly reproducible xenograft model for human ovarian carcinoma and application of MRI and ultrasound in longitudinal follow-up. Gynecologic Oncology. 2006;103(1):315-20.

[20]   Chen W, Thoburn C, Hess AD. Characterization of the Pathogenic Autoreactive T Cells in Cyclosporine-Induced Syngeneic Graft-Versus-Host Disease. J Immunol. 1998 December 15, 1998;161(12):7040-6.

[21]   Lee P, Rosen DG, Zhu C, Silva EG, Liu J. Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. GynecolOncol. 2005 03;96(3):671-7.

[22]   Cunat S, Hoffmann P, Pujol P. Estrogens and epithelial ovarian cancer. Gynecologic Oncology. 2004;94(1):25-32.

[23]   Ho S-M. Estrogen, Progesterone and Epithelial Ovarian Cancer. Reproductive Biology and Endocrinology. 2003;1(73).

[24]   van Doorn HC, Burger CW, van der Valk P, Bonfrer HMG. Oestrogen, progesterone, and androgen receptors in ovarian neoplasia: correlation between immunohistochemical and biochemical receptor analyses. J Clin Pathol. 2000 March 1, 2000;53(3):201-5.

[25]   Lee BH, Hecht J, L., , Pinkus JL, Pinkus GS. WT1, Estrogen Receptor, and Progesterone Receptor as Markers for Breast or Ovarian Primary Sites in Metastatic Adenocarcinoma to Body Fluids. American Journal of Clinical Pathology. 2002 May 2002;117(5):745-50.

[26]   Chadha S, Rao BR, Slotman BJ, van Vroonhoven CCJ, van der Kwast TH. An immunohistochemical evaluation of androgen and progesterone receptors in ovarian tumors. Human Pathology. 1993;24(1):90-5.

[27]   Ordóñez NG. Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas. Human Pathology. 2005;36(11):1163-7.

[28]   Verri E, Guglielmini P, Puntoni M, Perdelli L, Papadia A, Lorenzi P, et al. HER2/neu Oncoprotein Overexpression in Epithelial Ovarian Cancer: Evaluation of its Prevalence and Prognostic Significance. Oncology. 2005;68(2-3):154-61.

[29]   Nielsen JS, Jakobsen E, Holund B, Bertelsen K, Jakobsen A. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. International Journal of Gynecological Cancer. 2004;14(6):1086-96.

[30]   McCluggage WG, Strand K, Abdulkadir A. Immunohistochemical localization of metallothionein in benign and malignant epithelial ovarian tumors. International Journal of Gynecological Cancer. 2002;12(1):62-5.

[31]   Bayani J, Brenton JD, Macgregor PF, Beheshti B, Albert M, Nallainathan D, et al. Parallel Analysis of Sporadic Primary Ovarian Carcinomas by Spectral Karyotyping, Comparative Genomic Hybridization, and Expression Microarrays. Cancer Res. 2002 June 1, 2002;62(12):3466-76.

[32]   Surowiak P, Materna V, Kaplenko I, Spaczyński M, Dietel M, Lage H, et al. Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients. Virchows Archiv. 2005;447(3):626-33.

[33]   Yamada M, Tomida A, Yoshikawa H, Taketani Y, Tsuruo T. Increased expression of thioredoxin/adult T-cell leukemia-derived factor in cisplatin-resistant human cancer cell lines. Clin Cancer Res. 1996 February 1, 1996;2(2):427-32.

[34]   Wei S-H, Lin F, Wang X, Gao P, Zhang H-Z. Prognostic significance of stathmin expression in correlation with metastasis and clinicopathological characteristics in human ovarian carcinoma. Acta Histochemica. 2008;110(1):59-65.

[35]   Balachandran R, Welsh MJ, Day BW. Altered levels and regulation of stathmin in paclitaxel-resistant ovarian cancer cells. Oncogene. 2003;22(55):8924-30.

[36]   Alaiya AA, FranzÈn B, Fujioka K, Moberger B, Schedvins K, Silfversvärd C, et al. Phenotypic analysis of ovarian carcinoma: Polypeptide expression in benign, borderline and malignant tumors. International Journal of Cancer. 1997;73(5):678-82.

[37]   Martoglio AM, Tom BD, Starkey M, Corps AN, Charnock-Jones DS, Smith SK. Changes in tumorigenesis- and angiogenesis-related gene transcript abundance profiles in ovarian cancer detected by tailored high density cDNA arrays. Mol Med. 2000 Sep;6(9):750-65.

[38]   Ziltener HJ, Maines-Bandiera S, Schrader JW, Auersperg N. Secretion of bioactive interleukin-1, interleukin-6, and colony- stimulating factors by human ovarian surface epithelium. Biol Reprod. 1993 September 1, 1993;49(3):635-41.

[39]   Johanna G.W. Asschert EV, Marcel H. J. Ruiters, Elisabeth G. E. de Vries. Regulation of spontaneous and TNF/IFN-induced IL-6 expression in two human ovarian-carcinoma cell lines. International Journal of Cancer. 1999;82(2):244-9.

[40]   Wang ZY, Gaggero A, Rubartelli A, Rosso O, Miotti S, Mezzanzanica D, et al. Expression of interleukin-18 in human ovarian carcinoma and normal ovarian epithelium: Evidence for defective processing in tumor cells. International Journal of Cancer. 2002;98(6):873-8.

[41]   Bozkurt N, Yuce K, Basaran M, Gariboglu S, Kose F, Ayhan A. Correlation of serum and ascitic IL-12 levels with second-look laparotomy results and disease progression in advanced epithelial ovarian cancer patients. International Journal of Gynecological Cancer. 2006;16(1):83-6.

TABLE and FIGURE LEGENDS

Table 1. The survival time of rats corresponds to the number of FNAR cells injected intraperitoneally. The animals were monitored daily for overall general health as well as degree of abdominal extension and were sacrificed when appearing moribund.

Table 2. Gene chip analysis of FNAR shows similarities to human ovarian carcinoma. RNA was harvested from FNAR and REH endothelial cell lines and analyzed by GeneChip at a Johns Hopkins core facility. Data are presented as the relative expression of the gene in FNAR compared to expression in endothelial cells.

Figure 1. Proband shows tumor of the left ovary and intraperitoneal tumor studding (A). The tumor is an adenocarcinoma resembling human ovarian endometrioid carcinoma (B).

Figure 2. *In vitro* doubling time was measured by plating 10^4 cells into large flat bottom macrotiter wells. At the designated intervals, cells were harvested and counted. Data is presented as log number of tumor cells versus growth time. The slope of the line represents an estimate of the doubling time.

Figure 3. Flow cytometric evaluation of expression of ER (A), PR (B), AR (C), her-2/neu (D), and Ep-CAM (E). In all five graphs, isotypic control is shown with a solid line and the antibody of interest is shown with a shaded area.

Figure 4. FNAR tumor cells express IL-6, IL-12, and IL-18. Expression was assessed by qPCR. Data are standardized against GAPDH.

TABLE 1

Survival Following Tumor Challenge

| No. of Cells Injected	No. of Animals	Survival, Days[A] (No. of Animals)
5×10^4	N = 6	175 (6)
1×10^5	N = 8	150 (4) 155 (3), 160 (1)
5×10^5	N = 6	155 (2), 160 (4)
1×10^6	N = 6	150 (5), 152 (1)

[A]Animals were observed daily for general health and abdominal extension. The animals were sacrificed upon becoming moribund that was characterized by extreme lethargy, paleness and abdominal extension. The abdominal cavity was examined histologically for the presence of tumor cells in the peritoneal fluid and for tumor masses attached to the visceral organs and the abdominal wall


TABLE 2

Gene Expression Profiling of FNAR Cells

Gene Description	EST Accession #	Relative Expression
Metallothionein I	AW141679	11.38
Metallothionein II	AW916991	3.56
Thioredoxin	AW140607	3.07
Stathmin	BF281472	3.23
b-myb	RGIAC37	3.33

Sharrow Figure 1.

1

2

3   Sharrow Figure 2.

4

26

A

Isotype   ER

B

Isotype   PR

C

Isotype   AR

D

Isotype   Her-2/neu

E

Isotype   EpCAM

1   Sharrow Figure 3

2

IL-6

IL-12

IL-18

CYTOKINE

10^{-6} 10^{-5} 10^{-4} 10^{-3}

RELATIVE TRANSCRIPTS
(TARGET GENE / GAPDH)

3   Sharrow Figure 4.

1 **ARTICLE PRÉCIS**

2   This article describes a spontaneous rat model of ovarian carcinoma that

3 resembles the human endometrioid carcinoma subtype of surface epithelial neoplasms.